This article is more than 5 years old. Information may no longer be current.

Alcon begins phase 2 study on compound for viral conjunctivitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland — Alcon and NovaBay Pharmaceuticals announced that Alcon has started treating patients in a phase 2 clinical trial of NovaBay's lead Aganocide compound NVC-422 for viral conjunctivitis, the companies announced in a joint press release.

The multicenter, randomized, placebo-controlled clinical trial will enroll 250 patients and is designed to determine the safety and efficacy of NVC-422. The phase 2 viral conjunctivitis study follows the phase 1 trial in which safety and tolerability were successfully demonstrated in 120 healthy volunteers with no reported serious adverse events, the release said.

NVC-422 is an Aganocide developed by NovaBay that mimics the body's defense against infection. Because of its low potential for generating microbial resistance, NVC-422 offers a potential solution to the problem of rising resistance of microbes to traditional antibiotics.

"This study is an important step forward with the clinical program for this potentially dual-acting therapy to address the multiple causes of conjunctivitis," Sabri Markabi, MD, Alcon's senior vice president of research and development and chief medical officer, said in the release.